A recent in vivo study has shown that when WT-HRAS and WT-NRAS interact with mutated KRAS, specifically G12D in lung cancer, it effectively reduces KRAS dimerization, as well as decreases the amount of ERK downstream signaling. This evidence concerns the gene KRAS and lung carcinoma.